Protocol Ledger

NCT07020884 · Phase II · COMPLETED

A Study of ZT002 Injection With Subjects With Overweight or Obesity

Interventional Phase II clinical trial protocol NCT07020884 sponsored by Beijing QL Biopharmaceutical Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-08-14 Enrollment: 303 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07020884
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)303 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07020884
Protocol FieldVerified Registry Value
NCT IdentifierNCT07020884
Consolidated Lead SponsorBeijing QL Biopharmaceutical Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment303 participants (ACTUAL)
Registered Start Date2024-08-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07020884
Hospital Research SiteLocationSite Profile
Affiliated Hospital of Jiangsu UniversityZhenjiang, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI